Pharma major Lupin Limited (Lupin) won the gold award at the 9th Annual Conference on Quality Management, organised by the American Society for Quality (ASQ) at Ahmedabad on 22 November, 2019. The nomination case study submitted for this award summarised the transformation project to improve the yield and quality of Lupin's Cefadroxil products.
Speaking on the occasion, Rajendra B Chunodkar, President - Manufacturing Operations, Lupin Ltd. said, "It is a moment of pride. This is the fourth consecutive year that Lupin's Ankleshwar facility has won the Gold Award from the American Society for Quality. As a leading pharmaceutical company, we have constantly focused our efforts towards enabling manufacturing excellence at all our manufacturing sites. This award highlights and validates our approach toward quality and continuous improvement."
While, this year Lupin's nomination highlighted the key outcomes of its "Cefadroxil Yield and Quality Improvement" project, in the past three years, Lupin won the award for projects that focused on Ethambutol Yield Improvement (2018), 7AE Yield Improvement (2017) and 7ACCA Yield Improvement (2016).
Shares of LUPIN LTD. was last trading in BSE at Rs.774.95 as compared to the previous close of Rs. 770.8. The total number of shares traded during the day was 32406 in over 911 trades.
The stock hit an intraday high of Rs. 780.1 and intraday low of 764.7. The net turnover during the day was Rs. 25069180.